Neoadjuvant PD-1 blockade achieves encouraging clinical response in early-stage dMMR tumours
Findings from a small study support a non-surgical and tumour-agnostic approach with immunotherapy, but further research is needed
Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer
Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted antibody-drug conjugate in women receiving at least one prior topoisomerase-1 ADC
Shaping the future for young women facing breast cancer
Recent studies have refined current knowledge on how to better treat this patient population, taking care of their unique needs and expectations
TILs show value in predicting relapse risk in TNBC
Retrospective data suggest that patients with low baseline TILs and nodal involvement have poor prognosis despite achieving pathological complete response
Hortobagyi: “Patient involvement is central to advance research in breast cancer”
The 2025 ESMO Breast Cancer Awardee highlights that participation in clinical trials and the contribution of patient advocates is as relevant as technology to progress cancer care further
AI is transforming cancer diagnosis, but systemic barriers still hold it back
A new ESMO systematic review maps AI’s growing role in pathology and oncology, as well as challenges in its implementation due to infrastructure, regulatory framework and human factors
Peters: “Leadership can be isolating, especially for women”
In a video series produced by the ESMO Women for Oncology, Solange Peters reflects on her career and the leadership challenges she has faced
AI applications in oncology go beyond clinical practice
While many models and tools are designed to support clinical decision-making, AI is already serving cancer research for background tasks, with some potential to educate patients too
An ESMO roadmap for implementing molecular tumour boards
Newly released recommendations address key areas to facilitate the integration of precision oncology in clinical practice
Novel ways presented to mitigate combination therapy toxicity in EGFR-mutant advanced NSCLC
Results from the ETOP AMAZE-lung and COCOON trials show some promise to improve safety and reduce skin adverse events